Jalón Monzón Antonio, Alvarez Múgica Miguel, Fernández Gómez Jesús María, Martín Benito José Luis, Martínez Gómez Francisco, García Rodríguez Jorge, González Alvarez Roberto Carlos, Regadera Sejas Francisco Javier
Servicio de Urología-1, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.
Arch Esp Urol. 2007 Mar;60(2):125-36. doi: 10.4321/s0004-06142007000200004.
To evaluate the prognostic significance of the 2002 TNM tumor classification for renal cell carcinoma, as well as other factors intervening in its survival.
Retrospective chart review of 316 renal carcinomas operated between 1970 and 2003. Twenty-five prognostic variables were analyzed.
The histological type was renal cell carcinoma in 90.5% of the patients. Most tumors were T1b or T2, with a Fuhrman nuclear grade I or II. Mean tumor size was 7.17 +/- 3.4 cm. Most cases had a solitary tumor. 8.2% of the patients had lymph node involvement at the time of diagnosis, and 8.6% metastases. The most frequent clinical presentations were hematuria and/or pain. Mean follow-up was 57.8 months. 24.1% of the cases had recurrence, more than 50% of them during the first year. Advanced tumors (T3, T4) had the tendency to have a nuclear grade III-IV, bigger size, necrosis, vascular involvement, lymph node involvement, and metastases. At the end of follow-up, most patients were alive and disease free. The number of months free of disease, the presence of metastatic lymph nodes, the treatment of the first recurrence and the presence of anemia were independent factors for cancer specific mortality.
The modification of the current classification of renal tumors pT3 and pT4 would help to a better decision-making in the therapy of tumors with vascular, perirenal fat or adrenal involvement. Anemia and treatment of the first recurrence are important factors for cancer specific survival.
评估2002年TNM肿瘤分类对肾细胞癌的预后意义,以及其他影响其生存的因素。
对1970年至2003年间接受手术的316例肾癌患者进行回顾性病历审查。分析了25个预后变量。
90.5%的患者组织学类型为肾细胞癌。大多数肿瘤为T1b或T2期,Fuhrman核分级为I或II级。肿瘤平均大小为7.17±3.4 cm。大多数病例为单发肿瘤。8.2%的患者在诊断时出现淋巴结受累,8.6%出现转移。最常见的临床表现是血尿和/或疼痛。平均随访时间为57.8个月。24.1%的病例出现复发,其中超过50%在第一年复发。晚期肿瘤(T3、T4)倾向于具有III-IV级核分级、更大尺寸、坏死、血管受累、淋巴结受累和转移。随访结束时,大多数患者存活且无疾病。无病月数、转移性淋巴结的存在、首次复发的治疗以及贫血的存在是癌症特异性死亡率的独立因素。
对当前肾肿瘤pT3和pT4分类的修改将有助于在治疗伴有血管、肾周脂肪或肾上腺受累的肿瘤时做出更好的决策。贫血和首次复发的治疗是癌症特异性生存的重要因素。